

Edgar Filing: HAEMONETICS CORP - Form SC 13D/A

HAEMONETICS CORP
Form SC 13D/A
May 27, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 9) *

HAEMONETICS CORPORATION

(Name of Issuer)

Common Stock, Par Value \$0.01

(Title of Class of Securities)

405024100

(CUSIP Number)

Murray A. Indick
Blum Capital Partners, L.P.
909 Montgomery Street, Suite 400
San Francisco, CA 94133
(415) 434-1111

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

May 16, 2003

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [].

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 13

CUSIP NO. 405024100

SCHEDULE 13D

Page 2 of 13

1. NAME OF REPORTING PERSON

BLUM CAPITAL PARTNERS, L.P.

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

94-3205364

Edgar Filing: HAEMONETICS CORP - Form SC 13D/A

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☒ (b) ☒

3. SEC USE ONLY

4. SOURCE OF FUNDS* See Item 3

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) []

6. CITIZENSHIP OR PLACE OF ORGANIZATION California

7. SOLE VOTING POWER -0-

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
PERSON WITH

8. SHARED VOTING POWER 2,762,900**

9. SOLE DISPOSITIVE POWER -0-

10. SHARED DISPOSITIVE POWER 2,762,900**

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,762,900**

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES []

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 11.4%**

14. TYPE OF REPORTING PERSON PN, IA

** See Item 5 below

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP NO. 405024100

SCHEDULE 13D

Page 3 of 13

1. NAME OF REPORTING PERSON RICHARD C. BLUM & ASSOCIATES, INC.

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON 94-2967812

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☒ (b) ☒

3. SEC USE ONLY

4. SOURCE OF FUNDS* See Item 3

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

Edgar Filing: HAEMONETICS CORP - Form SC 13D/A

PURSUANT TO ITEMS 2(d) or 2(e) []

6. CITIZENSHIP OR PLACE OF ORGANIZATION California

7. SOLE VOTING POWER -0-

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
PERSON WITH

8. SHARED VOTING POWER 2,762,900**

9. SOLE DISPOSITIVE POWER -0-

10. SHARED DISPOSITIVE POWER 2,762,900**

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,762,900**

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES []

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 11.4%*

14. TYPE OF REPORTING PERSON CO

** See Item 5 below

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP NO. 405024100

SCHEDULE 13D

Page 4 of 13

1. NAME OF REPORTING PERSON BLUM STRATEGIC GP, L.L.C.
(Formerly RCBA GP, L.L.C.)

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON 94-3303831

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [x]
(b) [x]

3. SEC USE ONLY

4. SOURCE OF FUNDS* See Item 3

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) []

6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

7. SOLE VOTING POWER -0-

NUMBER OF
SHARES

8. SHARED VOTING POWER 2,762,900**

Edgar Filing: HAEMONETICS CORP - Form SC 13D/A

BENEFICIALLY
OWNED BY EACH
PERSON WITH

9.	SOLE DISPOSITIVE POWER	-0-
----	------------------------	-----

10.	SHARED DISPOSITIVE POWER	2,762,900**
-----	--------------------------	-------------

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,762,900**

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES []

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 11.4%**

14. TYPE OF REPORTING PERSON OO (Limited Liability Company)

** See Item 5 below

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP NO. 405024100

SCHEDULE 13D

Page 5 of 13

1. NAME OF REPORTING PERSON RICHARD C. BLUM

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON+

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [x]
(b) [x]

3. SEC USE ONLY

4. SOURCE OF FUNDS* See Item 3

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) []

6. CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A.

7. SOLE VOTING POWER -0-

NUMBER OF
SHARES

8.	SHARED VOTING POWER	2,762,900**
----	---------------------	-------------

BENEFICIALLY
OWNED BY EACH
PERSON WITH

9.	SOLE DISPOSITIVE POWER	-0-
----	------------------------	-----

10.	SHARED DISPOSITIVE POWER	2,762,900**
-----	--------------------------	-------------

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,762,900**

Edgar Filing: HAEMONETICS CORP - Form SC 13D/A

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES []

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 11.4%**

14. TYPE OF REPORTING PERSON IN

** See Item 5 below

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP NO. 405024100

SCHEDULE 13D

Page 6 of 13

1. NAME OF REPORTING PERSON BLUM STRATEGIC PARTNERS, L.P.
(Formerly RCBA Strategic Partners, L.P.)

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON 94-3303833

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [x]
(b) [x]

3. SEC USE ONLY

4. SOURCE OF FUNDS* WC

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) []

6. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

7. SOLE VOTING POWER -0-

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
PERSON WITH

8. SHARED VOTING POWER 2,762,900**

9. SOLE DISPOSITIVE POWER -0-

10. SHARED DISPOSITIVE POWER 2,762,900**

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,762,900**

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES []

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 11.4%**

14. TYPE OF REPORTING PERSON PN

** See Item 5 below

Edgar Filing: HAEMONETICS CORP - Form SC 13D/A

*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP NO. 405024100

SCHEDULE 13D

Page 7 of 13

This Amendment No. 9 amends the Statement on Schedule 13D (the "Schedule 13D") filed with the Securities and Exchange Commission (the "Commission") on June 15, 2001, by Blum Capital Partners, L.P., a California limited partnership ("BLUM L.P."); Richard C. Blum & Associates, Inc., a California corporation ("RCBA Inc."); Blum Strategic GP, L.L.C. (formerly RCBA GP, L.L.C.), a Delaware limited liability company ("BLUM GP"); Blum Strategic Partners, L.P. (formerly RCBA Strategic Partners, L.P.), a Delaware limited partnership ("Blum Strategic"); and Richard C. Blum, the Chairman and a substantial shareholder of RCBA Inc. and a managing member of BLUM GP (collectively, the "Reporting Persons"). This amendment to the Schedule 13D relates to the shares of Common Stock, \$0.01 par value (the "Common Stock") of Haemonetics Corporation, a Massachusetts corporation (the "Issuer"). The principal executive office and mailing address of the Issuer is 400 Wood Road, Braintree, MA 02184. The following amendments to the Schedule 13D are hereby made. Unless otherwise defined herein, all capitalized terms shall have the meanings ascribed to them in the Schedule 13D.

Item 2. Identity and Background

Item 2 of the Schedule 13D is hereby amended as follows:

Since the filing of Amendment No. 8 to Schedule 13D, there have been changes to the executive officers and directors of BLUM L.P. and RCBA Inc.

The principal business office address of BLUM L.P. and RCBA Inc. is 909 Montgomery Street, Suite 400, San Francisco, California 94133. The names of the executive officers and directors of RCBA Inc., their addresses, citizenship and principal occupations are as follows:

Name and Office Held	Business Address	Citizen- ship	Principal Occupation or Employment
Richard C. Blum President & Chairman	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	President & Chairman, BLUM L.P.
Nils Colin Lind Managing Partner & Director	909 Montgomery St. Suite 400 San Francisco, CA 94133	Norway	Managing Partner, BLUM L.P.
Claus J. Moller Managing Partner & Director	909 Montgomery St. Suite 400 San Francisco, CA 94133	Denmark	Managing Partner, BLUM L.P.
John C. Walker Partner	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner, BLUM L.P.
Kevin A. Richardson II Partner	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner, BLUM L.P.

CUSIP NO. 405024100

SCHEDULE 13D

Page 8 of 13

Edgar Filing: HAEMONETICS CORP - Form SC 13D/A

Name and Office Held	Business Address	Citizen- ship	Principal Occupation or Employment
-----	-----	-----	-----
Jose S. Medeiros Partner	909 Montgomery St. Suite 400 San Francisco, CA 94133	Brazil	Partner, BLUM L.P.
Kerry L. Nelson Partner	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner, BLUM L.P.
Jeffrey A. Cozad Partner	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner, BLUM L.P.
Marc T. Scholvinck Partner, Chief Financial Officer, Assistant Secretary & Director	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner & Chief Financial Officer, BLUM L.P.
Murray A. Indick Partner, General Counsel & Secretary	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner and General Counsel, BLUM L.P.

In February 2002, RCBA GP, L.L.C. and RCBA Strategic Partners, L.P. changed their names to Blum Strategic GP, L.L.C. and Blum Strategic Partners, L.P., respectively. The principal business of Blum GP is acting as general partner for Blum Strategic.

Since the filing of Amendment No. 8 to Schedule 13D, there have been changes to the members of BLUM GP.

The principal business office address of BLUM GP is 909 Montgomery Street, Suite 400, San Francisco, CA 94133. The names of the managing members and members of BLUM GP, their addresses, citizenship and principal occupations are as follows:

Name and Office Held	Business Address	Citizen- ship	Principal Occupation or Employment
-----	-----	-----	-----
Richard C. Blum Managing Member	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	President & Chairman, BLUM L.P.
Nils Colin Lind Managing Member	909 Montgomery St. Suite 400 San Francisco, CA 94133	Norway	Managing Partner, BLUM L.P.

CUSIP NO. 405024100

SCHEDULE 13D

Page 9 of 13

Name and Office Held	Business Address	Citizen- ship	Principal Occupation or Employment
-----	-----	-----	-----

Edgar Filing: HAEMONETICS CORP - Form SC 13D/A

Claus J. Moller Managing Member	909 Montgomery St. Suite 400 San Francisco, CA 94133	Denmark	Managing Partner, BLUM L.P.
John C. Walker Member	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner, BLUM L.P.
Kevin A. Richardson II Member	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner, BLUM L.P.
Jose S. Medeiros Member	909 Montgomery St. Suite 400 San Francisco, CA 94133	Brazil	Partner, BLUM L.P.
Kerry L. Nelson Member	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner, BLUM L.P.
Jeff A. Cozad Member	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner, BLUM L.P.
Marc T. Scholvinck Member	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner & Chief Financial Officer, BLUM L.P.
Murray A. Indick Member	909 Montgomery St. Suite 400 San Francisco, CA 94133	USA	Partner and General Counsel, BLUM L.P.

To the best knowledge of the Reporting Persons, none of the entities or persons identified in this Item 2 has, during the past five years, been convicted of any criminal proceeding (excluding traffic violations or similar misdemeanors), nor been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 5. Interest in Securities of the Issuer

Item 5 of the Schedule 13D is hereby amended as follows:

CUSIP NO. 405024100

SCHEDULE 13D

Page 10 of 13

(a), (b) According to the Issuer's most recent Form 10-Q, there were 24,237,965 shares of Common Stock issued and outstanding as of December 28, 2002. Based on such information, after taking into account the transactions described in Item 5(c) below, the Reporting Persons report beneficial ownership of the following shares of Common Stock: (i) 484,800 shares of Common Stock held by Blum L.P. and RCBA, Inc. on behalf of the limited partnerships for which Blum L.P. serves as the general partner, or on behalf of an entity for which Blum L.P. serves as investment advisor, which represents 2.0% of the outstanding shares of the Common Stock; (ii) 1,228,500 shares of Common Stock held by Blum GP on behalf of the limited partnership for which it serves as the general partner, which represents 5.1% of the outstanding shares of the Common Stock; and (iii) 811,700 shares of Common Stock that are legally owned by Carpenters

Edgar Filing: HAEMONETICS CORP - Form SC 13D/A

Pension Trust for Southern California ("Carpenters"), 45,700 shares of Common Stock that are legally owned by United Brotherhood of Carpenters Pension Plan ("UBC") and 192,200 shares of Common Stock that are legally owned by The Common Fund for the account of its Multi-Strategy Equity Fund ("The Common Fund")(collectively, the "Investment Advisory Clients"), with respect to which Blum L.P. has voting and investment power. The Investment Advisory Clients represent 4.3% of the outstanding shares of the Common Stock. The Common Fund is principally engaged in the business of managing investments for educational institutions. The principal administrative office of The Common Fund is located at 15 Old Danbury Road, Wilton, Connecticut 06897-0812. Each of the Investment Advisory Clients has entered into an advisory agreement with Blum L.P., but none of the Investment Advisory Clients has any contract, arrangement or understanding with any other Investment Advisory Client, or any other Reporting Person, with respect to the acquisition, ownership, disposition or voting of any shares of the Common Stock. Each of the Investment Advisory Clients disclaims membership in a group with any Reporting Person or with any other Investment Advisory Client, and each disclaims beneficial ownership of any shares beneficially owned by the Reporting Persons other than for their own account. Voting and investment power concerning the above shares are held solely by Blum L.P. and Blum GP. The Reporting Persons therefore may be deemed to be members in a group, in which case the group would be deemed to have beneficial ownership of an aggregate of 2,762,900 shares of the Common Stock, which is 11.40% of the outstanding Common Stock. As the sole general partner of Blum L.P., RCBA Inc. is deemed the beneficial owner of the securities over which Blum L.P. has voting and investment power. As Chairman, director and a substantial shareholder of RCBA Inc., Richard C. Blum might be deemed to be the beneficial owner of the securities beneficially owned by RCBA Inc. Additionally, Mr. Blum may be deemed to be the beneficial owner of the securities over which Blum GP has voting and investment power. Although Mr. Blum is joining in this Schedule as a Reporting Person, the filing of this Schedule shall not be construed as an admission that he, or any of the other shareholders, directors or executive officers of RCBA Inc., managing members and members of Blum GP, is, for any purpose, the beneficial owner of any of the securities that are beneficially owned by RCBA Inc. or Blum GP.

(c) During the last 60 days, the Reporting Persons sold the following shares of the Common Stock pursuant to Rule 144:

CUSIP NO. 405024100

SCHEDULE 13D

Page 11 of 13

Entity	Trade Date	Shares	Price/Share
-----	-----	-----	-----
Investment partnerships for	05-16-03	115,300	18.9799
which BLUM L.P. serves as the	05-20-03	20,900	18.3184
general partner and on behalf	05-21-03	24,700	18.2491
of an entity for which	05-22-03	18,500	18.1620
BLUM L.P. serves as investment			
advisor			

Entity	Trade Date	Shares	Price/Share
-----	-----	-----	-----
The Investment Advisory	05-16-03	249,300	18.9799
Clients for which BLUM L.P.	05-20-03	45,000	18.3184
serves as investment advisor	05-21-03	53,400	18.2491
	05-22-03	40,400	18.1620

Edgar Filing: HAEMONETICS CORP - Form SC 13D/A

(d) and (e) Not applicable.

Item 7. Material to be Filed as Exhibits

Exhibit A Joint Filing Undertaking.

CUSIP NO. 405024100

SCHEDULE 13D

Page 12 of 13

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: May 27, 2003

RICHARD C. BLUM & ASSOCIATES, INC.

BLUM CAPITAL PARTNERS, L.P.

By Richard C. Blum & Associates, Inc.
its general partner

By /s/ Murray A. Indick

By /s/ Murray A. Indick

Murray A. Indick
Partner, General Counsel,
Counsel, and Secretary

Murray A. Indick
Partner, General Counsel,
and Secretary

BLUM STRATEGIC GP, L.L.C.
(Formerly RCBA GP, L.L.C.)

By /s/ Murray A. Indick

Murray A. Indick, Member

BLUM STRATEGIC PARTNERS, L.P. (Formerly RCBA Strategic Partners, L.P.)

By BLUM STRATEGIC GP, L.L.C., its general partner

By /s/ Murray A. Indick

Murray A. Indick, Member

/s/ Murray A. Indick

RICHARD C. BLUM

By Murray A. Indick, Attorney-in-Fact

CUSIP NO. 405024100

SCHEDULE 13D

Page 13 of 13

Edgar Filing: HAEMONETICS CORP - Form SC 13D/A

Exhibit A
JOINT FILING UNDERTAKING

The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule jointly on behalf of each such party.

Dated: May 27, 2003

RICHARD C. BLUM & ASSOCIATES, INC.

BLUM CAPITAL PARTNERS, L.P.

By Richard C. Blum & Associates, Inc.
its general partner

By /s/ Murray A. Indick

By /s/ Murray A. Indick

Murray A. Indick
Partner, General Counsel,
Counsel, and Secretary

Murray A. Indick
Partner, General Counsel,
and Secretary

BLUM STRATEGIC GP, L.L.C.

By /s/ Murray A. Indick

Murray A. Indick, Member

BLUM STRATEGIC PARTNERS, L.P.

By BLUM STRATEGIC GP, L.L.C., its general partner

By /s/ Murray A. Indick

Murray A. Indick, Member

/s/ Murray A. Indick

RICHARD C. BLUM

By Murray A. Indick, Attorney-in-Fact